10 commercial payer policies list C86.6. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
10 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of C86.6 |
|---|---|---|
| Bortezomib Products | Feb 2, 2024 | Covered |
| Dendritic Cell Immunotherapy | Jun 6, 2023 | Covered |
| Flow Cytometry, Ektacytometry, DNA Ploidy, and S-phase Fraction | Jun 5, 2023 | Covered |
| Ibritumomab Tiuxetan (Zevalin) | Oct 11, 2023 | Covered |
| Pharmacogenetic and Pharmacodynamic Testing | Feb 27, 2024 | Covered |
| Plerixafor | Jan 9, 2024 | Covered |
| Tumor Markers | Mar 5, 2024 | Covered |
| Policy | Effective | Status of C86.6 |
|---|---|---|
| Breast Procedures; including Reconstructive Surgery, Implants and Other Breast Procedures | Jul 1, 2026 | Covered |
| Donor Lymphocyte Infusion for Hematologic Malignancies after Allogeneic Hematopoietic Progenitor Cell Transplantation | Jul 1, 2026 | Covered |
| Ultraviolet Light Therapy Delivery Devices for Home Use | Oct 1, 2026 | Covered |